Sponsors (4)
The bill aims to strengthen global and federal coordination to speed detection, development, and deployment of pandemic countermeasures—improving protection for Americans—but does so by increasing international commitments, taxpayer costs, and risks that domestic supply priorities, regulatory speed, or oversight could be constrained or skewed toward commercially attractive products.
Hospitals, clinics, and patients (including those with chronic conditions) will get faster detection, development, and access to vaccines, treatments, and diagnostics because the bill promotes international collaboration, federal coordination, and prioritization of pandemic products.
U.S. military personnel and state/local governments face lower cross‑border infectious‑disease risk because the bill supports partner‑country public‑health capacity and outbreak controls.
State governments, federal agencies (HHS/CDC), Congress, and taxpayers benefit from clearer criteria, reporting triggers, and coordinated U.S. leadership and technology‑sharing that improve oversight, decisionmaking, and equitable access during outbreaks.
Patients (especially those with chronic conditions), seniors, and hospitals risk delayed or reduced access to scarce countermeasures if international sharing and equitable allocation complicate or shift domestic supply priorities during crises.
U.S. taxpayers may face increased costs because the bill prioritizes international capacity‑building, coordination, and funding of multilateral or bilateral arrangements without guaranteed domestic returns.
Commercialization incentives could steer investment toward more profitable products rather than less‑profitable but critical public‑health needs, potentially leaving some threats inadequately addressed and harming patients and health systems.
Based on analysis of 4 sections of legislative text.
Directs the Secretary of State (with HHS) to produce and pursue an international strategy, due in 18 months, to accelerate development, commercialization, equitable access, and stewardship of qualified pandemic/epidemic products, including for AMR pathogens.
Introduced March 9, 2026 by Mike Levin · Last progress March 9, 2026
Requires the Secretary of State, working with the HHS Secretary and other agencies, to develop and submit to Congress within 18 months a whole-of-government strategy to secure international support and arrangements that accelerate development, commercialization, equitable access, stewardship, and regulatory pathways for qualified pandemic or epidemic products — including products targeting antimicrobial‑resistant (AMR) pathogens. The law also sets definitions for which pathogens and products count as priorities and directs the State Department (with HHS consultation) to seek arrangements with foreign governments and multilateral organizations to implement the strategy.